NO922528D0 - USE OF AN ANTICOAGULANT AS DIAGNOSTIC AGENT - Google Patents

USE OF AN ANTICOAGULANT AS DIAGNOSTIC AGENT

Info

Publication number
NO922528D0
NO922528D0 NO1992922528A NO922528A NO922528D0 NO 922528 D0 NO922528 D0 NO 922528D0 NO 1992922528 A NO1992922528 A NO 1992922528A NO 922528 A NO922528 A NO 922528A NO 922528 D0 NO922528 D0 NO 922528D0
Authority
NO
Norway
Prior art keywords
anticoagulant
esp
new
diagnostic agent
compsns
Prior art date
Application number
NO1992922528A
Other languages
Norwegian (no)
Other versions
NO305276B1 (en
NO922528L (en
Inventor
Christiaan Reutelingsperger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6396455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO922528(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO922528D0 publication Critical patent/NO922528D0/en
Publication of NO922528L publication Critical patent/NO922528L/en
Publication of NO305276B1 publication Critical patent/NO305276B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Dental Preparations (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticoagulant polypeptides (I) of the annexin family, labelled with a detectable marker are new. Also new are compsns. contg. (I) plus auxiliaries. (I) is esp. VAC (vascular anticoagulant protein) and suitable markers include fluorescein isothiocyanate, a radioisotope (esp. 131- or 125-iodine) or a paramagnetic contrast agent. (I), which can be administered intravenously or intraarterially, are formulated with physiological saline, 'Tween 80', arginine and/or phosphate buffer. The compsn. may also include an anticoagulant, esp. heparin, which has no effect on plasma Ca concn.
NO922528A 1989-12-27 1992-06-26 Use of an Anticoagulant Polypeptide as a Diagnostic Agent and Method for Detecting Prothrombic Condition NO305276B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3942988 1989-12-27
PCT/EP1990/002257 WO1991009628A1 (en) 1989-12-27 1990-12-19 Use of an anticoagulant as a diagnostic agent

Publications (3)

Publication Number Publication Date
NO922528D0 true NO922528D0 (en) 1992-06-26
NO922528L NO922528L (en) 1992-08-26
NO305276B1 NO305276B1 (en) 1999-05-03

Family

ID=6396455

Family Applications (1)

Application Number Title Priority Date Filing Date
NO922528A NO305276B1 (en) 1989-12-27 1992-06-26 Use of an Anticoagulant Polypeptide as a Diagnostic Agent and Method for Detecting Prothrombic Condition

Country Status (15)

Country Link
EP (2) EP0806670B1 (en)
JP (1) JP3135261B2 (en)
KR (1) KR0181520B1 (en)
AT (2) ATE429644T1 (en)
AU (1) AU642202B2 (en)
CA (1) CA2070647C (en)
DE (3) DE4040817A1 (en)
ES (1) ES2113372T3 (en)
FI (1) FI107586B (en)
HU (2) HUT61491A (en)
NO (1) NO305276B1 (en)
NZ (1) NZ236620A (en)
PT (1) PT96385B (en)
WO (1) WO1991009628A1 (en)
ZA (1) ZA9010319B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
ATE210464T1 (en) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA CONJUGATES AND THEIR USE IN PRETARGETING PROCEDURES
AU1186295A (en) * 1993-11-24 1995-06-13 University Of Washington Blood coagulation retardants and devices
CA2180555C (en) * 1994-01-24 2004-12-14 Sudhakar Kasina Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
CA2185653C (en) * 1994-03-16 2009-01-13 Kathleen M. Miller Stabilization of peptides and proteins for radiopharmaceutical use
US5834196A (en) * 1994-04-11 1998-11-10 Nexins Research B.V. Method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
DE69530841T2 (en) * 1994-06-16 2004-05-06 Neorx Corp., Seattle RADIOACTIVELY MARKED ANNEXIN GALACTOSE CONJUGATES
JPH10504534A (en) * 1994-06-16 1998-05-06 ネオルクス コーポレイション Radiolabeled annexin-galactose conjugate
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
EP1486509A3 (en) * 1994-12-07 2005-03-23 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
WO1996017618A1 (en) * 1994-12-07 1996-06-13 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5955605A (en) * 1995-02-21 1999-09-21 Neorx Corporation Biotinidase resistant biotin-DOTA conjugates
FR2736197B1 (en) * 1995-06-29 1997-09-12 Univ Paris Curie MAGNETIC NANOPARTICLES COUPLED WITH ANNEXIN AND THEIR USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
PT87083B (en) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int A PROCESS FOR THE PREPARATION OF A VASCULAR ANTICOAGULANT PROTEIN, OF DNA THAT CODIFIES FOR THIS PROTEIN AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING IT
DE3810331A1 (en) * 1988-03-26 1989-10-05 Boehringer Ingelheim Int Monoclonal VAC antibodies

Also Published As

Publication number Publication date
JP3135261B2 (en) 2001-02-13
NZ236620A (en) 1997-03-24
HU9202149D0 (en) 1992-10-28
ATE164083T1 (en) 1998-04-15
KR0181520B1 (en) 1999-05-01
FI922719A0 (en) 1992-06-12
AU7071191A (en) 1991-07-24
ES2113372T3 (en) 1998-05-01
DE59010815D1 (en) 1998-04-23
EP0806670A3 (en) 1997-12-10
WO1991009628A1 (en) 1991-07-11
DE4040817A1 (en) 1991-07-04
JPH05502877A (en) 1993-05-20
HUT61491A (en) 1993-01-28
EP0806670A2 (en) 1997-11-12
DE59010946D1 (en) 2009-06-04
NO305276B1 (en) 1999-05-03
EP0806670B1 (en) 2009-04-22
ZA9010319B (en) 1992-08-26
HU209650B (en) 1994-09-28
FI107586B (en) 2001-09-14
EP0509026A1 (en) 1992-10-21
KR920703121A (en) 1992-12-17
CA2070647A1 (en) 1991-06-28
AU642202B2 (en) 1993-10-14
EP0509026B1 (en) 1998-03-18
PT96385B (en) 1998-06-30
ATE429644T1 (en) 2009-05-15
PT96385A (en) 1991-10-31
CA2070647C (en) 2001-04-10
NO922528L (en) 1992-08-26

Similar Documents

Publication Publication Date Title
NO922528L (en) USE OF AN ANTICOAGULANT AS DIAGNOSTIC AGENT
Kelly et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons
SE8000469L (en) TISSUE BINDING AND PROCEDURE FOR ITS MANUFACTURING AND USING THE BINDING AGENT
ES2113532T3 (en) DEVICE FOR THE DETERMINATION OF THE FILLING LEVEL OF A BLOOD CIRCULATORY SYSTEM.
ATE123301T1 (en) GENETICALLY PRODUCED APROTININE HOMOLOGUE.
NO964007L (en) Combinations of thrombolytically active proteins and anticoagulants and their use
SE9103332L (en) METHOD FOR DIAGNOSIS OF BLOOD COAGULATION DISEASES
KR950703004A (en) INHIBITOR OF COLLAGEN-STIMULATED PLATELET AGGREGATION
DK0655089T3 (en) Effects of actin filaments on fibrin coagulate structure and lysis
NO913129D0 (en) NEW TROMBOLYTIC AGENT.
DK226889A (en) ALCOHOLPEPTIDE DERIVATIVES AND ITS USE TO REDUCE BLOOD COAGULATION
ES2078289T3 (en) AGENT TO IMPROVE THE ANEXINES RECOVERY.
BG97199A (en) ANTICOAGULANT PREPARATION
Al-Mondhiry et al. Platelet and fibrinogen survival in calves implanted with artificial heart and ventricular assist device-correlation with autopsy findings
Black Histocompatibility testing in the rabbit
FI885025A (en) KOAGULATIONSHAEMMANDE PROTEIN PP4-X, DESS FRAMSTAELLNING OCH ANVAENDNING.
Ramrakhyani et al. Hepatitis B viral markers and liver disease in haemophiliacs: A study in an Indian population
Hurlbut Deep venous thrombosis of the leg: US findings: Appleman PT, De Jong TE, Lampmann LE Radiology 163: 743–746 Jun 1987
DE69131248T2 (en) INHIBITION OF SEPARATION OF SODIUM BY NA-K-ATPASE
Shin et al. Effect of Cycloheximide on the Specific Activity of Na+-K+-activated Adenosine Triphosphatase in Human Neonatal Erythrocytes
SOLA Bradykinin and angiotensin release catechola-mines from the adrenal glands in cat, dog, rabbit, and rat. l-” With bronchoconstriction as an indicator, recent experiments have shown that bradykinin and angiotensin also release cate
FI903637A0 (en) DIAGNOSTIC ANALYSIS FOR THE CONDITION OF ANALYSIS OF CLINICAL TREATMENT.
ES2039304B1 (en) NON-OBSTRUCTING VASCULAR CATHETER OF THE BLOOD FLOW.

Legal Events

Date Code Title Description
MK1K Patent expired